Chiltern grows market share in FY 2010; plans global expansion

By Gareth Macdonald

- Last updated on GMT

Related tags: Contract research organization, Chiltern

CRO Chiltern International says market share grew in fiscal 2010, citing strengthened industrial relationships and global expansion as drivers.

For the 12-months ended March 31, the privately-owned contract research organisation (CRO) posted revenue of £81m (€97m), an increase of some 10 per cent on the amount earned in the previous financial year.

CEO Glenn Kerkhof said the year had seen considerable growth of new business awards, up 16 per cent to £134m, which “increased [Chiltern’s] market share.”

Kerkhof also​partly attributed Chiltern’s improved performance over the period to “[the] relationships we are building with our pharmaceutical and biotechnology clients​.”

He did not disclose which specific customers had been most important to Chiltern's business, other than to say that the firm's largest drug industry client had contributed 7.8 per cent of its revenue.

Global network

Kerkhof also hinted at Chiltern’s plans for the next 12-months, explaining that: “We continue to develop the Chiltern brand and expand our geographic network and are looking forward to another year of growth and development​.”

Again, while further information on the expansion was not forthcoming, the comments suggest the UK CRO’s recently​ opened offices in Australia and Singapore may not be the last it sets up over the next 12-months.

Further support for this idea comes from the fact that global growth has also been very much on the agenda at Chiltern’s owner Czura Thornton in recent times.

Speaking after​ the US investment group acquired Clearstone from MDS last year​, former Chiltern executive and Czua Thorton co-founder Nick Thornton said the contract services firms would work together to expand into new geographies.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more